Glucagon is a hormone that increases blood glucose levels in people with severe hypoglycemia. The medication can be taken in nasal spray form, or it can be injected into the skin.

STOCKHOLM — New data on a needle-free nasal delivery system for glucagon for use in severe hypoglycemia presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting here ...

The team found that 69 people had 157 HEs that were treated with the nasal glucagon. Their blood glucose levels ranged from 21.6 to 73.9 mg/dL.

Glucagon emergency kits are available with injectable versions of the hormone. FDA approval of Baqsimi in 2019 made the drug the first intranasal treatment for severe hypoglycemia.

(HealthDay News) — For patients with type 1 diabetes, intranasal glucagon is effective for treating insulin-induced hypoglycemia, according to a study published online in Diabetes Care. Michael ...

Nasal glucagon is approved for people as young as 4 years of age, so it fits a wide variety of patients. However, it's one dose of 3 mg.

Glucagon fill rates declined by 22% from 2.91 per 1,000 person-years in the first quarter of 2011 to 2.28 per 1,000 person-years in the first quarter of 2021.

Launched in 2019, Baqsimi has been used by people with diabetes as a nasally administered glucagon to treat severe hypoglycemia. “Baqsimi’s positive impact has been felt by people with diabetes around ...